SV Health Investors

Spectrawave is a medical device company that develops optical diagnostic and therapeutic devices. It enhances the diagnosis and treatment of cardiovascular diseases and primarily operates in the diagnostic equipment, medical business/industry. The Waltham, Massachusetts based company was founded in 2017.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, founded in 2016. The company specializes in developing bio-engineered surgical implants aimed at facilitating new tissue growth and aiding in connective tissue repair. Its primary product, the Bridge-Enhanced ACL Repair technology, offers a viable alternative to traditional anterior cruciate ligament (ACL) reconstruction for patients who have suffered ACL injuries. This innovative approach enables surgeons to restore the normal anatomy and function of the knee, enhancing recovery outcomes for patients.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Catamaran Bio is a biotechnology company focused on developing allogeneic immune cell therapies, specifically CAR-NK cell therapies, aimed at treating solid tumors and other cancers. The company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf therapeutic products that can address significant unmet medical needs. Founded in 2019 and headquartered in Cambridge, Massachusetts, Catamaran Bio is committed to providing transformative treatments through genetic engineering of NK cells, enabling easier access for medical practitioners and patients in need of effective cancer therapies.

Amwell is a telehealth platform based in the United States that connects healthcare providers, insurers, patients, and innovators to enhance access to affordable and high-quality medical care. Founded in 2006 and headquartered in Boston, the company offers a comprehensive platform to address various telehealth needs, including urgent and acute care, post-acute care, chronic care management, and healthy living. With over a decade of experience, Amwell serves more than 240 health systems, comprising 2,000 hospitals and 55 health plan partners, and reaches over 150 million individuals, including 36,000 employers. The platform supports both on-demand and scheduled consultations, providing solutions for primary care, specialty consults, and chronic care programs like musculoskeletal and dermatology care.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

Caraway Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases through the modulation of mitophagy and autophagy. By targeting genetically defined pathways, the company aims to create small molecules that restore cellular balance and address the underlying mechanisms of diseases such as Parkinson's disease and amyotrophic lateral sclerosis. Founded in 2018 and based in Cambridge, Massachusetts, Caraway Therapeutics seeks to improve the lives of patients affected by these debilitating conditions by leveraging its expertise in cellular degradation processes. The company was previously known as Rheostat Therapeutics, Inc. before rebranding in October 2019.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing therapeutics that leverage natural killer T (NKT) cells. Established in 2008, the company aims to create a pipeline of innovative NKT-based therapies targeting various conditions, including cancer, sickle cell disease, autoimmune and inflammatory diseases, as well as asthma. NKT Therapeutics utilizes its expertise to develop humanized monoclonal antibodies that specifically target and deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. Through its research and development efforts, the company seeks to address significant medical needs and improve treatment outcomes for patients suffering from these challenging conditions.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Soffio Medical is a Boston-based company that develops medical devices aimed at treating respiratory diseases. The company's innovative approach focuses on implantable devices designed to implement an airway bypass concept. This technology allows for the venting of trapped air from areas distal to high-resistance airways, which helps to reduce residual lung volume. By alleviating symptoms associated with chronic obstructive pulmonary disease, Soffio Medical's solutions aim to enhance the quality of life for patients suffering from these conditions.

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative therapies to improve the lives of cancer patients. The company aims to combat drug resistance mechanisms that hinder the effectiveness of existing cancer treatments. Its lead candidate, ripretinib, is designed for gastrointestinal stromal tumors and is also being evaluated in Phase I trials for various other cancers, including gliomas and melanoma. Additionally, Deciphera is advancing other clinical-stage candidates such as DCC-3014, targeting tenosynovial giant cell tumors, and Rebastinib, which is being assessed for solid tumors and in combination with chemotherapy. The company also has a preclinical candidate, DCC-3116, aimed at RAS mutant cancers. Deciphera's proprietary switch-control kinase inhibitor platform underpins its research and development efforts, supporting a diverse pipeline of drug candidates, including QINLOCK, which has received regulatory approval in multiple countries for specific cancer indications.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

KalVista Pharmaceuticals is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing small molecule protease inhibitors for diseases with unmet medical needs. The company's primary product portfolio features plasma kallikrein inhibitors aimed at treating hereditary angioedema (HAE) and diabetic macular edema (DME), a major cause of visual loss in adults. KalVista's notable products include KVD001, a plasma kallikrein inhibitor that has completed a Phase II clinical trial for DME, and KVD900, currently in Phase II trials for HAE attacks. Additionally, KVD824, an oral plasma kallikrein inhibitor, has completed a Phase I trial for both DME and HAE. The company also has a preclinical pipeline that includes a novel oral Factor XIIa inhibitor program, enhancing its commitment to addressing diverse therapeutic challenges.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for primary immune deficiencies and cancer. The company's lead candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. It is in Phase III for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and in Phase Ib for severe congenital neutropenia and Waldenström macroglobulinemia. Additionally, mavorixafor is being explored in Phase IIa trials for clear cell renal cell carcinoma. X4 Pharmaceuticals is also advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 for primary immune deficiencies. The company has partnered with Abbisko Therapeutics Co., Ltd. to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. and rebranded in March 2019.

CSA Medical, Inc. specializes in the development and manufacturing of spray cryotherapy medical devices. The company's flagship product, the truFreeze device, utilizes cold liquid nitrogen as a cryosurgical tool for the destruction of unwanted tissue in dermatology, gynecology, and general surgery, while facilitating the regrowth of healthy tissue. Additionally, CSA Medical offers the Rapid AV Spray Kit, which enhances the truFreeze system by reducing the time required for liquid nitrogen application. Originally founded as Crymed Technologies in 1993, the company rebranded to CSA Medical in April 2006. Headquartered in Lutherville Timonium, Maryland, CSA Medical also operates a research and development facility in Lexington, Massachusetts.

Soffio Medical is a Boston-based company that develops medical devices aimed at treating respiratory diseases. The company's innovative approach focuses on implantable devices designed to implement an airway bypass concept. This technology allows for the venting of trapped air from areas distal to high-resistance airways, which helps to reduce residual lung volume. By alleviating symptoms associated with chronic obstructive pulmonary disease, Soffio Medical's solutions aim to enhance the quality of life for patients suffering from these conditions.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany. The company is dedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, focused on genetic screening for inherited diseases. Founded in 2007, the company aims to transform reproductive medicine by providing physicians and patients with actionable insights into inherited genetic disorders. Good Start Genetics offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. The company employs advanced next-generation DNA sequencing technology, along with other established genetic screening methods, to deliver high carrier detection rates. Additionally, through its GoodStart Select program, it provides a comprehensive menu of genetic carrier screening tests for both known and novel mutations, all supported by a commitment to customer care and genetic counseling. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for rare and niche allergic and immunological diseases. The company focuses on bringing life-changing treatments to patients and families affected by these conditions. Its lead program, STAR-0215, is a monoclonal antibody that inhibits plasma kallikrein and is currently in preclinical development for hereditary angioedema. Additionally, Astria is developing STAR-0310, a monoclonal antibody OX40 antagonist, which is also in preclinical stages and targets atopic dermatitis, an immune disorder characterized by compromised skin barrier function and associated itching.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

NKT Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing therapeutics that leverage natural killer T (NKT) cells. Established in 2008, the company aims to create a pipeline of innovative NKT-based therapies targeting various conditions, including cancer, sickle cell disease, autoimmune and inflammatory diseases, as well as asthma. NKT Therapeutics utilizes its expertise to develop humanized monoclonal antibodies that specifically target and deplete iNKT cells, which are implicated in organ damage in preclinical models of sickle cell disease. Through its research and development efforts, the company seeks to address significant medical needs and improve treatment outcomes for patients suffering from these challenging conditions.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany. The company is dedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Adimab LLC is a biotechnology company based in Lebanon, New Hampshire, focused on the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007, Adimab utilizes an integrated antibody discovery platform that accelerates the process from antigen identification to the production of purified, full-length human IgGs. The company specializes in various antibody formats, including IgG, scFv, and CD3-based bispecific antibodies, which are designed to meet stringent criteria for affinity, epitope coverage, and cross-reactivity. Adimab's innovative approach enables its partners to enhance their biologics pipelines and effectively address therapeutic needs in areas such as cancer, autoimmune, and infectious diseases through a range of technology access arrangements.

Logical Therapeutics, Inc., a biopharmaceutical company, engages in the development of drugs to treat diseases caused by or associated with excessive inflammation. Its products include LT-NS001, a non-steroidal anti-inflammatory drug for the treatment of chronic inflammatory conditions, such as osteoarthritis; Leptin, a hormone for the regulation of normal body mass and metabolism; and TNF, a hormone that promotes the proliferation of hepatocytes. The company was founded in 2005 and is based in Waltham, Massachusetts.

GlycoFi is a biotech firm based in Lebanon, New Hampshire, focused on developing biotherapeutics through its innovative glycan optimization technology. The company has engineered a library of yeast strains that enable precise human glycosylation, resulting in therapeutic proteins suitable for drug development. GlycoFi aims to establish its own pipeline of therapeutic products while also collaborating with other pharmaceutical companies to enhance their drug offerings. Founded in 2000, GlycoFi operates as a subsidiary of Merck & Co., Inc., further expanding its capabilities in the biotherapeutics landscape.

Confluent Surgical develops products to address the need for surgical sealing and post-surgical adhesion prevention applications.The company provides DuraSeal, an adjunct to sutured dural repair during cranial surgeries to provide watertight closure. The company was founded in 1998 and is headquartered in Waltham, Massachusetts.

Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting conditions such as osteoarthritis, inflammation, and type II diabetes. Established in 2002 and located in Cambridge, Massachusetts, the company specializes in innovative therapeutic approaches, including Dipeptidyl and Peptidase IV inhibitors. In addition to its core areas, Alantos explores various tissue remodeling pathways to address a range of medical issues, including rheumatoid arthritis, liver fibrosis, cardiovascular conditions, chronic wound healing, and cancer.

Insulet Corporation is a medical device company dedicated to improving the lives of individuals with insulin-dependent diabetes through its innovative Omnipod System. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet develops, manufactures, and markets an insulin delivery system that includes a tubeless, disposable insulin infusion device and a handheld personal diabetes manager. The Omnipod System is designed for ease of use, allowing for automated cannula insertion and smartphone control for dosage management. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Since receiving FDA approval in 2005, the Omnipod System has been adopted by approximately 425,000 insulin-dependent diabetics worldwide, reflecting the company's commitment to enhancing diabetes management.

Insulet Corporation is a medical device company dedicated to improving the lives of individuals with insulin-dependent diabetes through its innovative Omnipod System. Founded in 2000 and headquartered in Acton, Massachusetts, Insulet develops, manufactures, and markets an insulin delivery system that includes a tubeless, disposable insulin infusion device and a handheld personal diabetes manager. The Omnipod System is designed for ease of use, allowing for automated cannula insertion and smartphone control for dosage management. Insulet primarily sells its products through independent distributors, pharmacy channels, and directly to patients in the United States, Canada, Europe, and the Middle East. Since receiving FDA approval in 2005, the Omnipod System has been adopted by approximately 425,000 insulin-dependent diabetics worldwide, reflecting the company's commitment to enhancing diabetes management.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing therapeutic aptamers for the prevention and treatment of various chronic and acute diseases. Established in 2000, the company’s notable product candidate is ARC1779, aimed at treating thrombotic microangiopathies and supporting carotid endarterectomy surgical procedures. In addition to this, Archemix is involved in developing other aptamer-based therapeutics targeting diseases in the fields of cardiovascular health, hematology, and oncology.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's technology and global services are designed to enable life sciences companies to automate and integrate the management of their entire clinical development process, from study initiation and FDA submission through post-marketing studies. Until its acquisition by Oracle in April 2010, Phase Forward was a publicly held company. Its corporate headquarters were in Waltham, Massachusetts, international headquarters in Maidenhead, UK, and its regional offices in the U.S., Japan, France and Australia. Phase Forward was founded in 1997 by Paul Bleicher, M.D, Ph.D., who had experienced firsthand the complexities involved in developing and conducting paper-based trials, in particular, capturing, managing, and growing volumes of data. Dr. Bleicher's vision was to develop technology that would enable organizations to make the shift from paper-based methods to Internet-enabled solutions. His pioneering efforts have contributed significantly to Phase Forward's evolution from initial concept to its current industry-leading position. Spearheading the evolution of electronic data capture (EDC) with its industry-leading InForm solution, Phase Forward transformed the way clinical data are collected, analyzed and managed. With the acquisition of Lincoln Technologies' innovative safety management solutions, Phase Forward took steps to provide the end-to-end solutions customers need to track and monitor product efficacy and safety, while building their trials more efficiently and cost-effectively.

GelTex Pharmaceuticals develops and markets non-absorbed polymer drugs that bind and eliminate targeted substances within the gastrointestinal tract. It also develops small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators. Its focus areas include hyperphosphatemia, hypercholesterolemia, cancer, iron overload, and infectious diseases. GelTex Pharmaceutics is based in Waltham Massachusetts.